Takeda clears final regulatory hurdle to completing its $62B Shire deal. Now only one obstacle remains
Takeda has just put the last regulatory piece in place for its $62 billion takeover of Shire. The European Commission has provided its blessing for the deal, with one requirement.
As expected, Takeda will have to divest SHP647 so it can retain its blockbuster drug Entyvio, where the Europeans saw an overlap. The other regulators involved in the US and Japan have already signed off.
Now there’s just one last obstacle to clear as CEO Christophe Weber looks to vault past a group of dissident Japanese shareholders and complete the journey into the top ranks of industry players.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.